Influx Healthtech Files For IPO On NSE Emerge to Fuel Expansion

Influx Healthtech Ltd, based in Mumbai has announced gearing up for an initial public offering (IPO) on NSE Emerge, with plans to fund some big expansion projects. The IPO includes a fresh issue of 46.32 lakh equity shares, along with an offer-for-sale (OFS) of 13.68 lakh shares from the company’s founder, Munir Abdul Ganee Chandniwala.

So, where’s all this money going? Rs.21.61 crore will be set aside to build a new manufacturing facility for their nutraceutical division, Rs.8.76 crore will go into setting up a veterinary food facility, and Rs.2.66 crore will be spent on machinery for their home care and cosmetic division. The remaining funds will help cover general corporate expenses.

A Quick Look at the Company

Founded in 2020, Influx Healthtech specializes in contract manufacturing for everything from nutraceuticals and cosmetics to veterinary feed, ayurvedic products, and home care. The company runs three manufacturing facilities in Palghar, Maharashtra.

In terms of financials, they had a good year in FY24, bringing in Rs.99.96 crore in revenue with a profit of Rs.11.22 crore, up from Rs.76.05 crore in revenue and Rs.7.19 crore in profit the year before.

Who’s Handling the IPO?

Corporate Capital Ventures is the sole book-running lead manager for the public issue, and Maashitla Securities is acting as the registrar.

Conclusion: Influx Healthtech is clearly aiming for bigger things with this IPO, using the funds to ramp up production across multiple divisions. With a good financial track record and ambitious growth plans, the company seems well-positioned for investors to keep an eye on how this plays out!

Want to stay ahead in the market? Get a sneak peek at our Upcoming IPO and invest early. Take the next step in your financial journey!

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.